UK biotech Exscientia has tapped the brakes on the rapid expansion of its R&D pipeline, narrowing its in-house activities to oncology programmes that it says offer the
Researchers in Finland have combined virtual drug screening with machine learning (ML) – carried out on supercomputers – to dramatically shorten the time taken to identify
German group Merck has revved up its artificial intelligence-powered drug discovery with partnerships with two UK companies – Exscientia and BenevolentAI – that will focus
AstraZeneca has made a sizeable play in applying artificial intelligence to drug discovery in its rare disease unit Alexion, partnering with Verge Genomics in a deal that
UK artificial intelligence (AI) specialist Intelligent Omics has entered into a research collaboration with Johnson & Johnson, within weeks of joining the big pharma's